AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan
Agreement strengthens AstraZeneca’s respiratory and immunology pipelineAstraZeneca will recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is currently in a Phase IIb/III programme in Crohn’s disease (CD)[1] and a Phase IIb trial in ulcerative colitis (UC).[2] AstraZeneca and Allergan will terminate their existing license agreement and all